Coya Therapeutics, Book Value Per Share vs. Profit Margin
| COYA Stock | 6.50 0.42 6.91% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 3.50611323 | Current Value 3.68 | Quarterly Volatility 1.11436406 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0667 | 0.0751 |
|
|
For Coya Therapeutics, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Coya Therapeutics, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Coya Therapeutics, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Coya Therapeutics,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Coya Therapeutics, Common over time as well as its relative position and ranking within its peers.
Coya |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Coya Therapeutics, Common Profit Margin vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Coya Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Coya Therapeutics, value to that of its competitors to determine the firm's financial worth. Coya Therapeutics, Common is rated below average in book value per share category among its peers. It is rated fourth in profit margin category among its peers . At present, Coya Therapeutics,'s Book Value Per Share is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Coya Therapeutics,'s earnings, one of the primary drivers of an investment's value.Coya Profit Margin vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Coya Therapeutics, |
| = | 2.10 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Coya Therapeutics, |
| = | (1.12) % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Coya Profit Margin Comparison
Coya Therapeutics, is currently under evaluation in profit margin category among its peers.
Coya Therapeutics, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Coya Therapeutics,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Coya Therapeutics, will eventually generate negative long term returns. The profitability progress is the general direction of Coya Therapeutics,'s change in net profit over the period of time. It can combine multiple indicators of Coya Therapeutics,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -10.1 K | -10.6 K | |
| Operating Income | -7.9 M | -8.3 M | |
| Income Before Tax | -7.3 M | -7.6 M | |
| Total Other Income Expense Net | 639.4 K | 671.3 K | |
| Net Loss | -11 M | -10.5 M | |
| Net Loss | -8 M | -8.4 M | |
| Income Tax Expense | 723.9 K | 862 K | |
| Net Loss | -12.4 M | -13 M | |
| Change To Netincome | 3.7 M | 3.9 M | |
| Net Loss | (0.79) | (0.83) | |
| Income Quality | 1.40 | 1.47 | |
| Net Income Per E B T | 1.10 | 0.88 |
Coya Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Coya Therapeutics,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Coya Therapeutics, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Coya Therapeutics,'s important profitability drivers and their relationship over time.
Use Coya Therapeutics, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coya Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coya Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Coya Therapeutics, Pair Trading
Coya Therapeutics, Common Pair Trading Analysis
The ability to find closely correlated positions to Coya Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coya Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coya Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coya Therapeutics, Common to buy it.
The correlation of Coya Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coya Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coya Therapeutics, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Coya Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Coya Therapeutics, position
In addition to having Coya Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Education Thematic Idea Now
Education
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
To fully project Coya Therapeutics,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Coya Therapeutics, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Coya Therapeutics,'s income statement, its balance sheet, and the statement of cash flows.